In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

Longtime runner Annie Saunders didn’t let a 2021 diagnosis of multiple sclerosis sideline her passions. If anything, the 40-year-old Irwin native pushes harder — through weakness and imbalance caused ...

RIVERSIDE, N.J. (WPVI) -- A multiple sclerosis diagnosis used to mean a future of disability. But now, a revolution in medications allows MS patients to pursue their dreams. Those medications are ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor (a group of drugs originally developed to treat lymphomas and related blood disorders) ...

COPENHAGEN, Denmark — Growing evidence supports the use of highly effective disease-modifying therapies for children with multiple sclerosis (MS). However, only few of these medications are licensed ...

Please provide your email address to receive an email when new articles are posted on . Children presented with unique MS symptoms, while adolescents’ issues aligned more with adults. Nearly half of ...

At the recent Consortium of Multiple Sclerosis Centers (CMSC) meeting, Ellen Mowry, MD, of John Hopkins University in Baltimore, presented the Presidential Lecture via livestream. Mowry described two ...

Zeposia (ozanimod) is a prescription drug used to treat certain forms of multiple sclerosis (MS) in adults. Zeposia is a brand-name drug and is not currently available in a generic version. Zeposia ...

An analysis of over 3,700 pregnancies of women with multiple sclerosis indicates that the therapy doesn’t lead to increased risks of miscarriage, premature birth or serious birth defects. Many women ...

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...